ELVN Stock Analysis: Enliven Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 3.559m USD | 12M Return: 159.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 90.2M
Warnings
Tailwinds
Seasonality 6.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Enliven Therapeutics, Inc. (NASDAQ: ELVN) is a clinical-stage biopharmaceutical company that discovers and develops small molecule inhibitors for patients with cancer. The company was founded in 2019, is headquartered in Boulder, Colorado, and completed its IPO in March 2020.
Its pipeline consists of two Phase 1 programs: ELVN-001, a small molecule kinase inhibitor in development for chronic myeloid leukemia (CML), and ELVN-002, a CNS-penetrant, irreversible HER2 inhibitor being evaluated in non-small cell lung cancer (NSCLC) and other HER2-mutant tumors.
As a clinical-stage biopharma in the Health Care sector, Enliven has no approved products or commercial sales, and its business model depends on R&D productivity, capital markets funding, and the eventual advancement or out-licensing of pipeline assets.
- ELVN-001 Phase 1 CML data readout drives stock volatility
- ELVN-002 HER2 lung cancer trial milestones advance pipeline
- Cash runway and capital raises support clinical development through key catalysts
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.14 > 0.02 and ΔFCF/TA 10.35 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.14 > 3% & CFO -65.5m > Net Income -98.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 40.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (62.8m) vs 12m ago 25.47% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.10%; Δ -0.10% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.97 (Total Current Assets 463.1m - Total Current Liabilities 11.5m) / Total Assets 464.9m |
| B: -0.80 (Retained Earnings -370.8m / Total Assets 464.9m) |
| C: -0.26 (EBIT TTM -98.8m / Avg Total Assets 383.7m) |
| D: 39.47 (Book Value of Equity 453.4m / Total Liabilities 11.5m) |
| Altman-Z'' = 43.48 = AAA |
As of July 08, 2026, the stock is trading at USD 50.92 with a total of 2,012,075 shares traded. Over the past week, the price has changed by +0.14%, over one month by +51.41%, over three months by +17.98% and over the past year by +159.93%.
Current recommended Stop Loss: 44.80 (which is 12% or 2.1 ATR below the current price).
Enliven Therapeutics has received a consensus analysts rating of 4.88. Therefore, it is recommended to buy ELVN.
- StrongBuy: 7
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 65.1 | 27.9% |
P/B = 7.6801
Revenue TTM = 0.0 USD
EBIT TTM = -98.8m USD
EBITDA TTM = -98.6m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 302k USD (from shortTermDebt, last quarter)
Debt = 302k USD (from shortLongTermDebtTotal, last quarter) (leases 302k already included)
Net Debt = -452.1m USD (calculated: Debt 302k - CCE 452.4m)
Enterprise Value = 3.11b USD (3.56b + Debt 302k - CCE 452.4m)
Interest Coverage Ratio = unknown (Ebit TTM -98.8m / Interest Expense TTM 0.0)
EV/FCF = -47.36x (Enterprise Value 3.11b / FCF TTM -65.6m)
FCF Yield = -2.11% (FCF TTM -65.6m / Enterprise Value 3.11b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 263k) / Revenue TTM)
Tobins Q-Ratio = 6.68 (Enterprise Value 3.11b / Total Assets 464.9m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 302k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -78.0m (EBIT -98.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 40.32 (Total Current Assets 463.1m / Total Current Liabilities 11.5m)
Debt / Equity = 0.00 (Debt 302k / totalStockholderEquity, last quarter 453.4m)
Debt / EBITDA = 4.59 (negative EBITDA) (Net Debt -452.1m / EBITDA -98.6m)
Debt / FCF = 6.89 (negative FCF - burning cash) (Net Debt -452.1m / FCF TTM -65.6m)
Total Stockholder Equity = 469.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -25.74% (Net Income -98.8m / Total Assets 464.9m)
RoE = -21.04% (Net Income TTM -98.8m / Total Stockholder Equity 469.4m)
RoCE = -21.04% (EBIT -98.8m / Capital Employed (Equity 469.4m + L.T.Debt 0.0))
RoIC = -17.20% (negative operating profit) (NOPAT -78.0m / Invested Capital 453.7m)
WACC = 11.19% (E(3.56b)/V(3.56b) * Re(11.19%) + D(302k)/V(3.56b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.19% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 85.40 | Cagr: 28.24%
[DCF] Fair Price = unknown (Cash Flow -65.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.31 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.36 | Chg30d=+10.83% | Revisions=+0% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.41 | Chg30d=+12.06% | Revisions=+25% | Analysts=3
EPS current Year (2026-12-31): EPS=-1.70 | Chg30d=+7.12% | Revisions=+40% | GrowthEPS=+7.4% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.33 | Chg30d=+2.45% | Revisions=+0% | GrowthEPS=-37.2% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +30% (up=5, down=2)